PMID- 11849457
OWN - NLM
STAT- MEDLINE
DCOM- 20020510
LR  - 20131121
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 61
IP  - 3
DP  - 2002 Mar
TI  - Angiotensin II infusion ameliorates the early phase of a mesangioproliferative 
      glomerulonephritis.
PG  - 1020-9
AB  - BACKGROUND: Inhibition of the renin-angiotensin system slows the progression of 
      chronic renal disease. METHODS: To test whether angiotensin II (Ang II) infusion 
      aggravates or ameliorates an acute glomerulonephritis, the peptide was infused 
      (200 ng/min by osmotic minipump) in rats with an anti-thymocyte antibody-induced 
      glomerulonephritis (ATS). RESULTS: Ang II significantly increased blood pressure. 
      Following injection of the antibody, similar glomerular binding of rabbit IgG and 
      rat complement C3 was detected in ATS and Ang II+ATS rats, indicating no 
      differences in delivery and binding of the antibody. Ang II infusion, however, 
      induced a significant reduction in glomerular monocyte infiltration, cell 
      proliferation and matrix expansion in nephritic rats compared to rats with 
      nephritis without Ang II. The antiproliferative effect of Ang II was inhibited by 
      the Ang II type 1 (AT1) receptor blocker irbesartan, but not by the AT2 receptor 
      blocker PD 123319, indicating that this effect was likely transduced by AT1 
      receptors. Norepinephrine infusion (600 ng/min) produced a similar degree of 
      hypertension, but did not affect glomerular proliferation in nephritic rats. Ang 
      II induced the glomerular expression of the cell cycle inhibitor p27KIP1 and of 
      transforming growth factor-beta (TGF-beta) and inhibited expression of monocyte 
      chemotactic protein 1 (MCP-1). CONCLUSION: Ang II surprisingly ameliorates 
      glomerular monocyte infiltration, proliferation and matrix expansion in ATS 
      nephritis. Ang II-mediated induction of cyclin kinase inhibitors and TGF-beta may 
      contribute to the protection of the glomerulus from inflammatory injury by 
      inducing cell cycle arrest and attenuating activation of local and recruited 
      cells. Alternatively, Ang II might protect the kidney at least in part by less 
      inflow of disease activators due to reduction of renal blood flow. Therefore, 
      activation of the renin-angiotensin system may have protective effects in certain 
      pathophysiological situations.
FAU - Wenzel, Ulrich O
AU  - Wenzel UO
AD  - Division of Nephrology, Department of Medicine, University of Hamburg, 
      Martinistrasse 52, 20246 Hamburg, Germany. wenzel@uke.uni-hamburg.de
FAU - Thaiss, Friedrich
AU  - Thaiss F
FAU - Helmchen, Udo
AU  - Helmchen U
FAU - Stahl, Rolf A K
AU  - Stahl RA
FAU - Wolf, Gunter
AU  - Wolf G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 0 (Cdkn1b protein, rat)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Complement C3)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Receptor, Angiotensin, Type 2)
RN  - 0 (Receptors, Angiotensin)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 11128-99-7 (Angiotensin II)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
CIN - Kidney Int. 2002 Mar;61(3):1176-7. PMID: 11849474
MH  - Angiotensin II/administration & dosage/*pharmacology
MH  - Animals
MH  - Cell Cycle Proteins/metabolism
MH  - Cell Division/drug effects
MH  - Complement C3/metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p27
MH  - Extracellular Matrix/metabolism
MH  - Glomerulonephritis, Membranoproliferative/metabolism/*pathology
MH  - Immunoglobulin G/metabolism
MH  - Infusion Pumps
MH  - Kidney Glomerulus/metabolism/pathology
MH  - Macrophages/pathology
MH  - Male
MH  - Monocytes/pathology
MH  - Norepinephrine/administration & dosage/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Angiotensin, Type 1
MH  - Receptor, Angiotensin, Type 2
MH  - Receptors, Angiotensin/physiology
MH  - Transforming Growth Factor beta/metabolism
MH  - Tumor Suppressor Proteins/metabolism
MH  - Vasoconstrictor Agents/administration & dosage/pharmacology
EDAT- 2002/02/19 10:00
MHDA- 2002/05/11 10:01
CRDT- 2002/02/19 10:00
PHST- 2002/02/19 10:00 [pubmed]
PHST- 2002/05/11 10:01 [medline]
PHST- 2002/02/19 10:00 [entrez]
AID - S0085-2538(15)48311-5 [pii]
AID - 10.1046/j.1523-1755.2002.00192.x [doi]
PST - ppublish
SO  - Kidney Int. 2002 Mar;61(3):1020-9. doi: 10.1046/j.1523-1755.2002.00192.x.